AU2013248220B2 - Polymorphs - Google Patents
Polymorphs Download PDFInfo
- Publication number
- AU2013248220B2 AU2013248220B2 AU2013248220A AU2013248220A AU2013248220B2 AU 2013248220 B2 AU2013248220 B2 AU 2013248220B2 AU 2013248220 A AU2013248220 A AU 2013248220A AU 2013248220 A AU2013248220 A AU 2013248220A AU 2013248220 B2 AU2013248220 B2 AU 2013248220B2
- Authority
- AU
- Australia
- Prior art keywords
- polymorph
- methyl
- xanthine
- ray powder
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 claims abstract description 8
- 238000004519 manufacturing process Methods 0.000 claims abstract 2
- 238000010586 diagram Methods 0.000 claims description 13
- 238000002425 crystallisation Methods 0.000 claims description 11
- 239000000155 melt Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 230000011514 reflex Effects 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 10
- LTXREWYXXSTFRX-QGZVFWFLSA-N Linagliptin Chemical compound N=1C=2N(C)C(=O)N(CC=3N=C4C=CC=CC4=C(C)N=3)C(=O)C=2N(CC#CC)C=1N1CCC[C@@H](N)C1 LTXREWYXXSTFRX-QGZVFWFLSA-N 0.000 claims description 9
- 238000001816 cooling Methods 0.000 claims description 9
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 8
- 238000001914 filtration Methods 0.000 claims description 8
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 5
- 150000001875 compounds Chemical class 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- 238000007865 diluting Methods 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 238000010992 reflux Methods 0.000 claims description 4
- 239000011877 solvent mixture Substances 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 238000000034 method Methods 0.000 claims 15
- 239000013078 crystal Substances 0.000 abstract description 9
- 230000004048 modification Effects 0.000 abstract description 9
- 238000012986 modification Methods 0.000 abstract description 9
- 229940075420 xanthine Drugs 0.000 abstract description 3
- 238000002360 preparation method Methods 0.000 abstract description 2
- 102000004207 Neuropilin-1 Human genes 0.000 abstract 1
- 108090000772 Neuropilin-1 Proteins 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 description 6
- 102100025012 Dipeptidyl peptidase 4 Human genes 0.000 description 6
- 238000002372 labelling Methods 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- -1 4-methylquinazolin-2-yl Chemical group 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 2
- 208000001280 Prediabetic State Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 201000009104 prediabetes syndrome Diseases 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 1
- RAQYQYKCJCPROF-LLVKDONJSA-N 8-[(3R)-3-aminopiperidin-1-yl]-7-but-2-ynyl-1-ethyl-3H-purine-2,6-dione Chemical compound C(C)N1C(=O)NC=2N=C(N(C2C1=O)CC#CC)N1C[C@@H](CCC1)N RAQYQYKCJCPROF-LLVKDONJSA-N 0.000 description 1
- 102000055006 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 108010016626 Dipeptides Proteins 0.000 description 1
- 101000908391 Homo sapiens Dipeptidyl peptidase 4 Proteins 0.000 description 1
- 101150029237 Il11 gene Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 208000020442 loss of weight Diseases 0.000 description 1
- 150000004682 monohydrates Chemical class 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
H:\rec\ntenvven\NRP1\DCC\REC\5 %5 OC-24/ 2 Abstract The invention relates to polymorphic crystal modifications of 1-[(4-methylquinazolin-2 yl)niethyl]-3 -methyl-7-(2-butvn-1 -yl)-8-( 3 -(R)-amino-piperi din-1 -yl)-xanthine, their production and their use for the preparation of a drug.
Description
H:\rec\tevven\N>RP,1bIlDCC\REC\T %53_LDOC-24/JO/20,3 -1 Polymorphs This application is a divisional of Australian Patent Application No. 2007247190, the entire content of which is incorporated herein by reference. The invention relates to polymorphous crystal modifications of a DPP-IV inhibitor, the preparation thereof and the use thereof for preparing a medicament. The enzyme DPP-IV, also known by the name CD26, is a serine protease which promotes the cleaving of dipeptides in proteins with a proline or alanine group at the N-terminal end. DPP-IV inhibitors thereby influence the plasma level of bioactive peptides including the peptide GLP-L Compounds of this type are useful for the prevention or treatment of illnesses or conditions which are associated with an increased DPP-IV activity or which can be prevented or alleviated by reducing the DPP-IV activity, particularly type I or type 11 diabetes mellitus, prediabetes, or reduced glucose tolerance. WO 2004/018468 describes DPP-IV inhibitors with valuable pharmacological properties. One example of the inhibitors disclosed therein is 1-[(4-methylquinazolin-2-yl )methyl]-3 m ethyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine. Within the scope of the present invention it has been found that 1-[(4-methylquinazolin-2 yl)methyl]-3-methyl-7-(2 -butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine may take on various polymorphous crystal modifications and that the compound prepared in WO 2004/018468 is present at ambient temperature as a mixture of two enantiotropic poly morphs. The temperature at which the two polymorphs transform into one another is 25±15'C (see Figures 1 and 2). The pure high temperature form (polymorph A), which can be obtained by heating the mixture to temperatures >40'C, melts at 206±3'C. In the X-ray powder diagram (see Figure 3) this form shows characteristic reflexes at the following d values: 11.49 A, 7.60 A, 7.15 A, 3.86 A, 3.54 A and 3.47 A (cf. also Table I and 2). Anhydrous polymorph A may be prepared by WO 2007/128721 PCT/EP2007/054201 -2 (a) refluxing 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R) amino-piperidin-1-yl)-xanthine in absolute ethanol and optionally filtering the mixture, (b) cooling the hot solution or the hot filtrate until crystallisation sets in, 5 (c) diluting with a solvent such as tert.-butylmethylether, (d) suction filtering the solvent mixture and (e) drying the polymorph A at 45*C in vacuo. The low temperature form (polymorph B) is obtained by cooling to temperatures 10 <10 *C. In the X-ray powder diagram (see Figure 4) this form shows characteristic reflexes at the following d values: 11.25 A, 9.32 A, 7.46 A, 6.98 A and 3.77 A (cf. also Table 3 and 4). Anhydrous polymorph B may be prepared by 15 (a) dissolving 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 (R)-amino-piperidin-1-yl)-xanthine in absolute ethanol and refluxing and optionally filtering the mixture, (b) cooling the hot solution or the hot filtrate for crystallisation to a temperature below 10*C, 20 (c) diluting with a solvent such as tert.-butylmethylether, (d) suction filtering the solvent mixture and (e) drying the polymorph at a temperature below 10*C in vacuo. Another polymorph (polymorph C) shows characteristic reflexes in the X-ray powder 25 diagram (see Figure 5) at the following d values: 12.90 A, 11.10 A, 6.44 A, 3.93 A and 3.74 A (cf. also Table 5). Polymorph C is obtained if (a) 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3-(R)-amino 30 piperidin-1-yl)-xanthine is dissolved in methanol and refluxed and optionally filtered in the presence of activated charcoal, (b) the methanolic solution is cooled to a temperature of 40-60*C, WO 2007/128721 PCTIEP2007/054201 -3 (c) a solvent such as tert.-butylmethylether or diisopropylether is added, (d) the resulting suspension is first of all cooled slowly to 15-25*C and then later to 0-5 0 C, (e) the crystals formed are suction filtered and washed again with tert.
5 butylmethylether or diisopropylether and (f) the crystals thus obtained are dried at a temperature of 70*C in the vacuum dryer. Another polymorph (polymorph D) melts at 150±3 *C. This polymorph is obtained if 10 polymorph C is heated to a temperature of 30-1 00*C or dried at this temperature. Finally, there is also polymorph E. which melts at a temperature of 175±3*C. Anhydrous polymorph E is formed if polymorph D is melted. On further heating, polymorph E crystallises out of the melt. 15 The polymorphs thus obtained may be used in the same way as the mixture of the two polymorphs A and B described in WO 2004/018468 for preparing a pharmaceutical composition which is suitable for treating patients with type I and type 11 diabetes mellitus, prediabetes or reduced glucose tolerance, with rheumatoid 20 arthritis, obesity, or calcitonin-induced osteoporosis, as well as patients in whom an allograft transplant has been carried out. These medicaments contain in addition to one or more inert carriers at least 0.1% to 0.5%, preferably at least 0.5% to 1 5% and particularly preferably at least 1 % to 3% of one of the polymorphs A, B, or C.
WO 2007/128721 PCT/EP2007/054201 -4 The following Examples are intended to illustrate the invention in more detail. Example 1 Crystallisation of polymorph A Crude 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino 5 piperidin-1-yl)-xanthine is refluxed with 5 times as much absolute ethanol and the hot solution is filtered clear through activated charcoal. After the filtrate has been cooled to 20*C and crystallisation has set in, the solution is diluted to double the volume with tert.-butylmethylether. Then the suspension is cooled to 2*C, stirred for 2 hours, suction filtered and dried in the vacuum dryer at 450C. 10 Polymorph A melts at 206 ± 3 *C. In the DSC diagram another slightly endothermic signal can be seen at approx. 25*C. This is a fully reversible solid-solid phase transition between the two enantiotropic crystal modifications A and B. The form A is 15 the thermodynamically stable modification above this transformation temperature, while form B is the thermodynamically stable modification below this transformation temperature. Figure 2 shows a cyclic DSC diagram, in which the phase transition from -40 0C to 20 120 *C and vice versa has been run through a total of 3 times. During heating, the phase transition is observed as an endothermic signal and, correspondingly, during cooling it is observed as an exothermic signal. During the first heating cycle the phase transition may also be observed as an endothermic double signal or as a very broad signal while in all the other cycles the signal occurs as a very sharp 25 endothermic or exothermic signal, depending on whether heating or cooling is taking place.
WO 2007/128721 PCT/EP2007/054201 Table 1: Labelled X-ray reflexes up to 30 * 2 0 with intensities (standardised) for the anhydrous polymorph A 2 0 intensity dhkI labelling d__ expeaic [0] 1110 [%] [A] h k I [A] 5.56 1 15.89 1 0 0 -0.008 7.18 32 12.31 0 1 1 0.005 7.62 100 11.59 1 1 0 0.007 8.49 20 10.41 -1 1 1 0.002 9.91 24 8.92 0 0 2 0.003 10.41 18 8.49 0 2 0 0.024 11.18 24 7.91 2 0 0 0.038 11.63 41 7.60 -1 1 2 0.003 12.37 59 7.15 -1 2 1 -0.003 13.19 6 6.71 1 2 1 -0.014 13.45 3 6.58 -2 0 2 0.007 14.05 6 6.30 2 1 1 0.011 14.38 6 6.16 0 2 2 0.003 14.71 10 6.02 -1 2 2 -0.008 15.26 13 5.80 2 2 0 0.001 15.76 10 5.62 -1 1 3 0.008 16.09 1 5.51 1 2 2 -0.010 16.32 1 5.43 2 0 2 0.035 16.69 4 5.31 2 2 1 -0.007 17.03 3 5.20 -1 3 1 0.026 17.63 6 5.03 1 3 1 0.006 18.17 5 4.88 -1 2 3 -0.004 18.78 7 4.72 -1 3 2 -0.014 19.30 1 4.60 -2 3 1 -0.019 19.61 2 4.52 -3 2 1 0.036 19.86 20 4.47 -2 2 3 0.040 20.29 10 4.37 2 0 3 0.019 20.57 4 4.31 0 1 4 0.006 21.12 1 4.20 3 0 2 0.048 21.57 12 4.12 -2 1 4 0.028 22.46 10 3.96 1 4 1 0.035 WO 2007/128721 PCT/EP20071054201 -6 2 e intensity dhkI labelling dexp.calc [*] /Il [%] [A] h k I [A] 23.03 35 3.86 4 1 0 0.022 23.39 21 3.80 -1 4 2 0.019 24.08 2 3.69 -3 1 4 -0.006 24.51 1 3.63 -4 0 3 0.036 24.91 10 3.57 -2 4 2 0.003 25.14 39 3.54 3 1 3 0.043 25.69 36 3.47 -3 3 3 0.041 26.68 3 3.34 0 5 1 0.035 26.90 2 3.31 3 4 0 0.027 27.10 2 3.29 0 2 5 0.030 27.42 3 3.25 4 3 0 0.006 28.19 2 3.16 -1 5 2 -0.035 28.54 2 3.12 3 0 4 0.047 28.94 11 3.08 0 4 4 -0.036 29.18 5 3.06 -4 3 3 0.017 29.50 4 3.03 -1 0 6 0.041 30.18 7 2.96 -1 5 3 -0.042 Table 2: Lattice metrics of the anhydrous form A Symmetry: monocline spatial group: P a: 16.16(2) A b: 17.02(1) A c_ 18.18(2) A B __ 100.95(6) * ce olume 4907(11)A 5 Example 2 Crystallisation of polymorph B Polymorph B is obtained by cooling form A from Example 1 to temperatures <10 *C.
WO 2007/128721 PCT/EP2007/054201 -7 5 Table 3: Labelled X-ray reflexes up to 30 2 - with intensities (standardised) for the anhydrous form B 2 0 intensity dhkI labelling dexp-caic [0] 110 [%] [A] h k I [A] 5.82 3 15.17 1 0 0 -0.007 7.04 33 12.55 0 1 1 0.001 7.82 100 11.3 1 1 0 -0.004 8.84 11 10 -1 1 1 0.001 9.44 40 9.36 1 1 1 0.011 10.62 14 8.32 -1 0 2 0,013 10,79 24 8.19 0 1 2 -0.005 11.82 39 7.48 -1 1 2 -0.003 12.64 53 7 -1 2 1 -0.009 13.07 11 6.77 1 2 1 -0.006 13.24 6 6.68 -2 1 1 0.004 14.04 16 6.3 2 1 1 0.003 15.23 17 5.81 -2 1 2 0.003 15.70 22 5.64 2 2 0 0.016 16.38 2 5.41 0 3 1 -0.010 16.73 6 5.3 2 2 1 0.008 17.67 8 5.02 0 2 3 0.014 18.16 3 4.88 -1 2 3 0.005 18.33 9 4.84 3 1 0 0.016 18.48 10 4.8 -3 1 1 -0.003 18.97 15 4.68 0 0 4 -0.001 19.56 6 4.54 1 3 2 0.013 WO 2007/128721 PCT/EP2007/054201 -8 2 8 intensity dhkl labelling dexp-calc [*] 1110 [%] [A] h k [A] 20.00 17 4.44 2 1 3 0.000 20.42 9 4.35 1 0 4 0.009 20,76 4 4.27 3 0 2 -0.014 20.97 4 4.23 0 4 0 0.010 21.07 5 4.21 1 1 4 -0.009 21.22 12 4.18 0 3 3 0.001 21.40 7 4.15 3 2 1 0.004 21.66 4 4.1 -1 3 3 0.018 21.98 7 4.04 2 2 3 -0.003 22.16 10 4.01 -3 1 3 0.008 22.97 3 3.87 1 2 4 -0.006 23.58 43 3.77 -2 3 3 -0.003 23,78 15 3.74 -2 2 4 -0.004 24.05 6 3.7 4 1 0 -0.002 24.29 8 3.66 -2 4 1 -0.008 24.46 5 3.64 3 3 1 0,018 24.71 7 3.6 0 3 4 0.001 24.96 23 3.56 2 3 3 -0.001 25.45 12 3.5 -2 4 2 -0.010 25.75 35 3.46 4 2 0 0.011 25.99 4 3.43 3 2 3 0.014 26.15 6 3.41 3 3 2 0.010 26.57 12 3.35 -2 3 4 -0.001 26.82 4 3.32 -3 2 4 0.011 27.20 6 3.28 1 2 5 -0.010 27.43 4 3.25 -2 4 3 -0.003 27.60 3 3.23 -2 2 5 -0.005 28.19 4 3.16 3 4 1 0.010 28.40 15 3.14 0 4 4 -0.013 28.64 12 3.11 0 0 6 0.016 WO 2007/128721 PCT/EP2007/054201 2 0 intensity dhki labelling dexp.ac [*] 1Il [%] [A] h k I [A] 29.18 6 3.06 -4 3 2 0.004 29.42 2 3.03 1 4 4 0.002 29.99 10 2.98 0 5 3 -0.008 30.77 3 2.9 -4 3 3 0.018 Table 4: Lattice metrics of the anhydrous form B Symmetry: monocline spatial group: P2 1 /c (# 14) a: 15.23(1) A b: 16.94(1) A c: 18.79(1) A 95.6(2)* cell volume: 4823(3) A 5 Example 3 Crystallisation of polymorph C Crude 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino piperidin-1-yl)-xanthine (26 kg) is refluxed with 157 1 methanol, combined with 1.3 kg of activated charcoal and after 30 minutes' stirring the mixture is filtered and rinsed with 26 1 methanol. 122 I of methanol are distilled off from the filtrate, then the 10 residue is cooled to 45-55*C. 52 1 of tert.-butylmethylether are added to the residue over 30 minutes. Then the mixture is stirred for another 60 minutes at 45-55 0 C. Crystallisation takes place within this time. A further 78 I tert. butylmethylether are added to the suspension over 30 minutes and then it is stirred again for a further 60 minutes at 45-55 0 C. It is diluted to four times the volume. The suspension is slowly 15 cooled to 15-25*C and stirred overnight at this temperature. After the suspension has been cooled to 0-5*C the crystals are suction filtered, washed with 2 batches terL-butylmethylether and dried at 70*C in the vacuum dryer.
WO 2007/128721 PCT/EP2007/054201 -10 Table 5: X-ray reflexes up to 30 2 E) with intensities (standardised) for the anhydrous form C 2 E dhki intensity 2 E dhki intensity 2 0 dhkl intensity [*] [A] 1/10 [%] [*] [A] 11I [] [A] Il11 [%] 3.38 26.16 4 14.38 6.16 17 21.96 4.05 4 6.85 12.90 100 14.74 6.01 11 22.59 3.93 26 7.18 12.31 11 14.95 5.92 10 23.76 3.74 29 7.52 11.74 14 15.63 5.66 6 24.68 3.60 6 7.96 11.10 36 16.28 5.44 5 25.01 3.56 7 9.80 9.02 3 17.81 4.98 10 25.57 3.48 4 11.11 7.96 2 18.33 4.83 6 25.96 3.43 4 11.58 7.64 3 18.75 4.73 15 26.93 3.31 18 12.30 7.19 5 20.51 4.33 8 27.22 3.27 13 13.30 6.65 16 20.77 4.27 8 27.92 3.19 10 13.75 6.44 26 21.47 4.14 3 5 Example 4 Crystallisation of polymorph D Polymorph C is obtained if polymorph C from Example 3 is heated to a temperature of 30-1 00*C or dried at this temperature. 10 Example 5 Crystallisation of polymorph E Anhydrous polymorph E is obtained if polymorph D is melted. On further heating, polymorph E crystallises out of the melt. 15 In the DSC diagram of form C a whole range of signals can be observed. The strongest signal is the melting point of the anhydrous form A at approx. 206 *C, which is produced in the DSC experiment. Before the melting point a number of other endothermic and exothermic signals can be observed. Thus, for example, a very broad and weak endothermic signal can be seen between 30 and 100*C, which 20 correlates with the main loss of weight in thermogravimetry (TR). A TG/IR coupling H:\ectevoven\NRP,1bIlDCC\REC\5 Y%53_LDOC-24/JO/20u3 11 experiment provides the information that only water escapes from the sample in this temperature range. An X-ray powder diagram taken of a sample maintained at a temperature of 100'C shows different X-ray reflexes from the starting material, suggesting that form C is a hydrate phase with stoichiometry somewhere in the region of a hemihydrate or monohydrate. The temperature-controlled sample is another anhydrous modification D, which only stable under anhydrous conditions. The D form melts at approx. 150C. Another anhydrous crystal modification E crystallises from the melt, and when heated further melts at approx. 175 C. Finally, form A crystallises from the melt of form E. Form E is also a metastable crystal modification which occurs only at high temperatures. Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "compri sing", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps. The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
Claims (15)
1. A method of preparing anhydrous polymorph A of the compound 1-[(4-methyl quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3-(R)-amino-piperidin-1 -yl) xanthine, characterised in that it melts at 206 ± 3 C, wherein polymorph A is prepared by (a) refluxing 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3 (R)-amino-piperidin-1-yl)-xanthine in absolute ethanol and optionally filtering the mixture, (b) cooling the hot solution or the hot filtrate until crystallisation sets in, (c) diluting with a solvent such as tert-butylmethylether, (d) suction filtering the solvent mixture and (e) drying the polymorph A at 450C in vacuo; or by heating polymorph B or a mixture of polymorphs A and B to temperatures >40C.
2. Method according claim 1, wherein polymorph A is characterised in that in the X-ray powder diagram it has inter alia characteristic reflexes at the following d values: 11.59 A, 7.60 A, 7.15 A, 3.86 A, 3.54 A and 3.47 A.
3. A method of preparing anhydrous polymorph B of the compound 1-[(4-methyl quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3-(R)-amino-piperidin-1 -yl) xanthine, characterised in that at a temperature of 10-40C it transforms reversibly into the polymorph A of claim 1, wherein polymorph B is prepared by (a) dissolving 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino piperidin-1-yl)-xanthine in absolute ethanol and refluxing and optionally filtering the mixture, (b) cooling the hot solution or the hot filtrate for crystallisation to a temperature below 10 C, (c) diluting with a solvent such as tert.-butylmethylether, H:\rbr\Intrwovn\NRPortbl\DCC\RBR\8828903_l.docx-8/12/2015 - 13 (d) suction filtering the solvent mixture and (e) drying the polymorph at a temperature below 10 C in vacuo; or by cooling polymorph A or a mixture of polymorphs A and B to temperatures <10 C.
4. Method according claim 3, wherein polymorph B is characterised in that in the X-ray powder diagram it has inter alia characteristic reflexes at the following d values: 11.25 A, 9.32 A, 7.46 A, 6.98 A and 3.77 A.
5. Use of one of the polymorphs A or B of the compound 1-[(4-methyl-quinazolin-2 yl)methyl]-3-methyl-7-(2-butyn-1 -yl)-8-(3-(R)-amino-piperidin-1 -yl)-xanthine as prepared according to any one of claims 1 to 4 in the manufacture of a medicament for the treatment of patients with type || diabetes mellitus.
6. The method according to claim 1 or 2, wherein polymorph A is characterised by its lattice metrics: Symmetry: monocline spatial group: P a: 16.16(2) A b: 17.02(1) A c: 18.18(2) A B: 100.95(6)0 cell volume: 4907(11) A 3
7. The method according to claim 3 or 4, wherein polymorph B is characterised by its lattice metrics: Symmetry: monocline spatial group: P2 1 /c (# 14) a: 15.23(1) A H:\rbr\Intrwovn\NRPortbl\DCC\RBR\8828903_l.docx-8/12/2015 - 14 b: 16.94(1) A C: 18.79(1) A B: 95.6(2) cell volume: 4823(3) A 3
8. The method according to claim 1, 2 or 6, wherein the X-ray powder diagram of polymorph A is substantially as shown in Figure 3.
9. The method according to claim 3, 4 or 7, wherein the X-ray powder diagram of polymorph B is substantially as shown in Figure 4.
10. The method according to claim 1, 2, 6 or 8, wherein the X-ray powder diagram of polymorph A is substantially free of the characteristic reflexes of polymorph B according to claim 4.
11. The method according to claim 3, 4, 7 or 9, wherein the X-ray powder diagram of polymorph B is substantially free of the characteristic reflexes of polymorph A according to claim 2.
12. A method of preparing a medicament, wherein polymorph A or B, prepared by a method according to any of the preceding claims, is combined with one or more inert carriers.
13. The method according to claim 12, wherein said medicament contains 0.1% to 0.5% of polymorph A or B in addition to one or more inert carriers.
14. The method according to claim 12, wherein said medicament contains 0.5% to 1.5% of polymorph A or B in addition to one or more inert carriers.
15. The method according to claim 12, wherein said medicament contains 1% to 3% of polymorph A or B in addition to one or more inert carriers.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2013248220A AU2013248220B2 (en) | 2006-05-04 | 2013-10-24 | Polymorphs |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06009202.0 | 2006-05-04 | ||
AU2007247190A AU2007247190A1 (en) | 2006-05-04 | 2007-04-30 | Polymorphs |
AU2013248220A AU2013248220B2 (en) | 2006-05-04 | 2013-10-24 | Polymorphs |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2007247190A Division AU2007247190A1 (en) | 2006-05-04 | 2007-04-30 | Polymorphs |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2013248220A1 AU2013248220A1 (en) | 2013-11-14 |
AU2013248220B2 true AU2013248220B2 (en) | 2016-01-28 |
Family
ID=48445972
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2013203622A Active AU2013203622B2 (en) | 2006-05-04 | 2013-04-11 | Polymorphs |
AU2013248220A Active AU2013248220B2 (en) | 2006-05-04 | 2013-10-24 | Polymorphs |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2013203622A Active AU2013203622B2 (en) | 2006-05-04 | 2013-04-11 | Polymorphs |
Country Status (1)
Country | Link |
---|---|
AU (2) | AU2013203622B2 (en) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040097510A1 (en) * | 2002-08-21 | 2004-05-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
-
2013
- 2013-04-11 AU AU2013203622A patent/AU2013203622B2/en active Active
- 2013-10-24 AU AU2013248220A patent/AU2013248220B2/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040097510A1 (en) * | 2002-08-21 | 2004-05-20 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
Also Published As
Publication number | Publication date |
---|---|
AU2013203622B2 (en) | 2016-03-10 |
AU2013203622A1 (en) | 2013-05-02 |
AU2013248220A1 (en) | 2013-11-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11919903B2 (en) | Polymorphs | |
AU2013248220B2 (en) | Polymorphs | |
CA1299576C (en) | Process for the production of tizanidine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FGA | Letters patent sealed or granted (standard patent) |